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 1.5% of bead reactions were affected by prozone  
 Using ROC curve analysis, EDTA has >90% sensitivity and ~100% specificity in 
overriding the prozone effect due to complement mediated interference (CMI) 
 Twenty percent of an unselected sensitised post-transplant cohort display CMI in 





INTRODUCTION:  Single antigen bead (SAB) testing for HLA-specific antibody enables 
efficient organ allocation and aids in the diagnosis of antibody mediated rejection. In this 
retrospective cohort study, a population of kidney transplant recipients possessing HLA 
Class I antibodies was used to evaluate the best method for resolving complement 
interference, the so called “prozone” effect. The aim was to compare the use of EDTA versus 
a Biotin-Streptavidin Complex (BSC) as methodological approaches for abating the prozone 
effect using a fixed 1 in 10 dilution as validation.   
METHODS:  One hundred and seventeen patients transplanted in our centre between 2009-
2014 were identified as having class I HLA-specific antibody(-ies) using a Labscreen® Mixed 
assay. Positive sera underwent class I HLA-specific SAB testing; for comparison a standard 
SAB with and without EDTA, BSC and dilution (1 in 10) modifications were utilized.  Samples 
were processed on the Luminex platform generating 11349 bead reactions for analysis. 
RESULTS:  We identified sera from 23 patients giving rise to 170 bead reactions showing 
complement interference.  Using linear modelling, we observed slightly higher MFIs on 
average in both EDTA and BSC modifications when compared to the standard assay, 
allowing the nominal threshold MFI of 2000 in the standard assay to be adjusted to 2097 
and 2033 in the EDTA and BSC assays respectively.  We calculated 99% prediction intervals 
(PI) to establish outlier bead reactions for each assay.  The 1 in 10 dilution was used as a 
crosscheck for determining which prozone reactions were overcome by EDTA and BSC. 
Using ROC curve analysis, EDTA was found to be ~90% sensitive and 100% specific compared 
to BSC which was ~60% sensitive and 100% specific in ameliorating prozone positive 
reactions at the thresholds defined by linear models. 
DISCUSSION:  Our data indicates that both EDTA and BSC are suitable assays in overcoming 
CMI.  We recommend that all clinical laboratories adopt a validated assay designed 
specifically to abrogate CMI for all potential renal transplant recipients, as the standard 
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Single antigen bead (SAB) assays for identifying HLA-specific antibody have been a major 
asset to the renal transplant community, enabling sensitive and specific determination of 
pre-transplant sensitisation to class I and class II Human Leukocyte Antigens (HLA) and in the 
investigation of antibody mediated rejection (AbMR) post-transplant.  SAB assays have 
helped to establish more efficient peri-transplant protocols by allowing patients to proceed 
to transplant without performing a prospective physical crossmatch. Thorough evaluation of 
patient sensitisation using SAB assays resulted in acceptance of the so-called virtual 
crossmatch (VXM) to become widely utilised world-wide.  This is particularly significant in 
deceased donor transplantation where opportunities to reduce cold ischaemia are valuable. 
The basic premise of SAB testing is that each bead represents a single HLA molecule.  A 
patient’s serum is applied to the beads, and any HLA-specific antibody(-ies) in the serum will 
bind to beads expressing the corresponding epitopes. A fluorescently labelled anti-human 
IgG antibody is then applied, generating a signal referred to as mean fluorescence intensity 
(MFI). Any beads displaying an MFI value above a pre-determined threshold indicate the 
patient has HLA-specific antibody(-ies) to the antigen(s) on those beads 
Various limitations to the SAB assays have been reported both in terms of false negativity 
and false positivity [1].  The focus of this paper is primarily on false negativity.  The 
mechanisms leading to false negative results are believed to be attributable to two linked 
phenomena, namely steric hindrance and the so called “prozone effect”.  Simply put, steric 
hindrance, is overcrowding, where a sufficiently high concentration of patient’s antibody 
prevents binding of the HLA-specific antibody to its corresponding bead, giving a lower 
signal on the SAB test than would normally be expected [2], [3].  The prozone effect also 
occurs when there is high concentration of anti-HLA antibody. Prozone is reliant on the close 
spatial relationship of anti-HLA antibodies which results in the formation of immune 
complexes which interfere with the binding of the detection antibody; these include 
complement mediated processes [4] and IgM [5].  Johannes F.M Jacobs et al demonstrated 
these effects; Figure 1 has been redrawn on the basis of their work.  In particular, c and d 
show steric hindrance and complement fixation leading to immune complex formation 
which impedes binding of the detection molecule (we refer to this effect as the prozone 




Figure 1 A):  a) A non-saturating concentration of HLA specific antibody binds to SABs with 
increasing MFI; b) the assay is saturated with high concentration antibody providing 
maximum signal; c) There is redundancy in the assay with excess antibody that cannot bind, 
but in the absence of inhibitory influences the maximum signal is still achieved; d) very high 
concentration of antibody causes overcrowding which impedes access of antibody to its 
binding sites on the SABs, thereby reducing MFI; e) The prozone effect is caused by 
complement fixing antibodies bound to SABs triggering the formation of complement 
mediated immune complexes which inhibit binding of the secondary detection antibody and 
so MFI is reduced (following Johannes F.M Jacobs et al); B):  A detailed representation of 
complement-mediated interference (a.k.a. ‘‘prozone” effect). The large C1qrs and C3d 
complex, bound to primary HLA antibody and residing on the surface of the bead, are 
thought to sterically block the binding of PE-conjugated anti-Ig secondary antibody.  
Reproduced with permission from H Gebel and R Bray [7]. 
A suggested mechanism for EDTA’s ability to mitigate the prozone is its disruption of the 
binding of complement component C1 to the Fc portion of IgG1 and IgG3 which is a calcium 
dependent process [4], [8].  EDTA is inexpensive, widely available and its use incorporated 
as standard practice in many laboratories worldwide. However, there are concerns that 
EDTA has potential limitations as its chelation of heavy metal ions is non-specific. Chemically 
altering the serum may have effects on the SAB assay through mechanisms not yet 
understood [9]. 
 = SAB 
 = HLA-specific Antibody from patient serum 
 = detection antibody - goat anti-Human IgG 
conjugated PE  





An experimental modification to the standard SAB test has been suggested using a Biotin-
Streptavidin complex (BSC).   Work by Bray and Gebel has shown that using a BSC approach 
can mitigate the prozone effect [7], [10]–[12].  This assay overcomes prozone and steric 
hindrance by using an additional binding step in which a Biotin conjugated secondary 
antibody binds with high avidity to the primary antibody, followed by a tertiary step wherein 
streptavidin (which has a high affinity for Biotin) conjugated to phycoerythrin (PE), becomes 
the reporter probe. The postulated mechanism of action for this assay is the relationship 
between steric hindrance and prozone.  PE is a large molecule with a mass of approximately 
240kDa compared to the filamentous Biotin whose mass is 0.24kDa (x1000 smaller) meaning 
that the biotin-conjugated secondary antibody can negotiate overcrowding and/or the rigid 
structure of immune complexes and bind to primary antibodies on the single antigen beads, 
whereas the bulky PE-conjugate cannot do so directly.  The Biotin molecule is attached to 
the immunoglobulin via a 6-atom spacer thereby extending the biotin molecule away from 
the antibody surface and facilitating the binding of the avidin-PE conjugate at a distance 
from the immunoglobulin [7], [10], [12].   
Previous studies have inconsistently defined the prozone effect; methods range from 
stratifying MFI increases with EDTA treatment into categories of magnitude of prozone 
effect [9], [13] to a doubling of MFI values between the standard assay and the peak MFI in 
the assay modifications adopted [14].   An additional confounder is that  sera are often 
collected from highly sensitised patients [13], [14] which is independently associated with 
prozone and hence potentially introducing bias into evaluations of the assay.  
One study, using sera from an  unselected population of pre- and post-transplant, patients   
reported a prevalence of complement interference (prozone) in the SAB assay of 29.5% of 
patients involving class I HLA antibodies and 45.9% involving  class II antibodies with HLA-A 
and HLA-DQ antibodies the most prevalent [15]. In contrast, studies using sera from highly 
sensitised subjects (cPRA >95%), show a higher prevalence of class I HLA-specific antibodies 
demonstrating prozone (>70%) [13], [14].  Improving detection of and understanding the 
prozone effect will help to optimise the utilisation of SABs in transplantation whilst ensuring 
maximum peri-transplant efficiency is retained. 
2.  Objective 
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In this cohort study, we evaluated sera collected from a population of kidney transplant 
recipients from the Royal Liverpool Hospital. Patients received a renal transplant between 
2009 and 2014 and had post-transplant sera stored and available for testing.  The aims were 
threefold:  to compare EDTA and BSC assays to the standard assay in order to observe the 
overall relationship between MFIs among the tests to allow for adjustment of the nominal 
MFI threshold for the assay modifications in data analysis; to compare EDTA and BSC tests 
with regard to abrogating/mitigating complement interference of class I HLA-specific 
antibodies; and to formally define prozone numerically. 
3. Materials & Methods 
Ethical approval was granted from the Health Research Authority National Research Ethics 
Service, study number 11/NW/0279 and the local Research and Development Department, 
who acted as sponsors, reference number 4049. Patients had received a kidney transplant 
at the Royal Liverpool Hospital between 2009 and 2014.  
Following informed consent, all samples available for each patient at 2 weeks, 1 month, 3 
months, 6 months, 9 months, 12 months and then yearly following transplant underwent a 
Labscreen® Mixed screening assay (LSM12, Lot 17) to broadly determine the presence or 
absence of Class I or Class II HLA-specific antibodies.  Briefly, screening assays were 
performed as per manufacturers protocol (Labscreen® negative control, One Lambda).  A 
locally validated modification utilised a vacuum suction to dry the plates between washes, 
which has been shown to have no adverse effect on MFIs generated [16][17].   
The plate was then placed in the Luminex machine (Lx-200) to determine the Mean 
Fluorescent Intensity (MFI) for class I and class II HLA-specific antibodies for each sample.  A 
normalised MFI was generated (raw MFI minus negative control value for the serum), with a 
local policy defining a positive result as a normalised MFI of ≥500.  Results were interpreted 
using HLA Fusion 3.0 software and raw data processed using Microsoft Excel.   
Samples with a positive MFI for class I were retained for single antigen bead testing.  For 
each patient, only the first positive sample for class I was tested.  The technique for testing 
with single antigen beads was the same as that used for the Labscreen® Mixed assay, 
however, the threshold for a positive result was locally set at a normalised MFI of ≥2000 and 
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the beads were specific for single Class I: HLA Labscreen® Single Antigen HLA Class I – Combi 
(lot numbers 9 and 10). 
The single antigen bead assay was performed for the EDTA and 1 in 10 dilution modified 
assays in the same manner as for the standard detection assay with the following 
differences: 
 For EDTA treatment, 95µL of serum was mixed with 5µL of pre-prepared 6% EDTA 
(weight/volume) and put on the roller for 5 minutes prior to use.   
 For 1 in 10 dilutions, 10µL of patient serum was mixed with 90µL PBS and put on the 
roller for 5 minutes prior to use. A fixed dilution was used for convenience and has 
been reported in the literature as an acceptable alternative to serial dilutions 
[14][18].   
 For the BSC assay, the standard Luminex assay was performed as described 
previously, until the addition of the secondary antibody.  At this point, 95uL of a 
1:250 dilution (locally established protocol based on manufacturers range of 
recommended titrations) of an anti-Human IgG goat antibody conjugated to Biotin 
(Biotin-SP®, Lot 120783) was added to each well and incubated at room temperature 
for 30 minutes.  Then, four additional wash steps were performed, and 95uL of a 
1:100 concentration of phycoerythrin-conjugated streptavidin (Streptavidin, R-
Phycoerythrin Conjugate (SAPE), Lot 1755577) was added to each of the dry wells.  
The plate was incubated for 15 minutes followed by four additional wash steps.  The 
beads were resuspended in 80uL of PBS as per the standard Luminex protocol.   
For data analysis, the initial MFI values were normalised, following standard lab practice 
(the total raw MFI minus the negative control). This gave a range of MFIs values covering 
five orders of magnitude. Data covering such a large range of values generates a 
disproportionate variability in the low MFI range, thus, to determine global relationships 
without undue interference from this effect, data were transformed by taking natural 
logarithms. Linear regression analysis was performed on log (normalised) MFI values, both 
with and without outlier removal. Linear regression without outlier removal was used to 
demonstrate the global linear relationship between different test types, as indicated by the 
r2 value which is described in the supplemental information (Supplementary File – S. Figure 
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1).  The global relationship permits the development of prediction intervals, based only on 
values that show standard method-to-method variation, beyond which candidates for 
suspected prozone / steric hindrance effects are identified. 
In the data analysis shown, the creation of the linear model is performed with outlier 
removal to avoid any interference from reactions at i) the upper register - containing the 
majority of prozone reactions, which would introduce pre-test bias; ii) the lower register - a 
high level of variation is observed even following log transformation, including values of 0 
(an artifact of the normalisation process) – see Figure 2.  Thus, the range of MFI values used 
for creating the linear regression was log MFI >5 (MFI >148) and log MFI <9.5 (MFI 
<13359.7) for EDTA and BSC and log MFI > 2.5 (MFI > 12) and log MFI < 9.5 (MFI <13360) for 
the dilution test, where MFI values are lower in non-prozone affected reactions.   
Following development of the linear models (outliers removed), the trend line was mapped 
onto the whole dataset without outlier removal. Prediction intervals (PIs) were calculated at 
99% from the linear models, to indicate that 99% of values would be expected to fall within 
this region and mapped onto the whole dataset. Any values beyond the prediction intervals 
could thus be classified as unusual results, for example indicative of prozone effect. As 
noted in the Results, different subsets of data were defined for analysis of outliers from PIs, 
false positive analysis and false negative analysis.  
To determine the sensitivity and specificity of the EDTA and BSC modifications, the standard 
assay versus fixed 1 in 10 dilution regression analysis was used to facilitate identification of 
prozone positive, prozone negative and prozone indeterminate candidates (Figure 2D).  
These were defined, as a “gold standard” against which EDTA and Biotin results were 
compared for their MFI recovery of prozone positive reactions.  
To be identified as a prozone positive candidate, the dilution series value was higher than 
the upper limit for the 99% PI for standard versus dilution. In addition, prozone positive 
candidates had log MFI of the dilution sample >6.98 (MFI 1074.9). This threshold was 
calculated as the equivalent prediction from linear modelling the dilution series against the 
standard test, and taking the upper limit of the 75% PI for a log MFI of 7.6 (typical threshold 
of 2000). The rationale for this threshold was to include only data that was considered to be 
certainly positive at a clinically relevant threshold i.e. the test results would certainly pass 
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the typical MFI > 2000 threshold used elsewhere. Thus, the prozone positive set was 170 
data points (Figure 3A), 1.5% of the bead reactions examined.  
To be defined as prozone negative, we calculated a 90% prediction interval for the dilution 
series versus the standard test. Prozone negative was thus defined as any value less than 
the upper prediction interval in this regression analysis i.e. there was no evidence from the 
regression that these values were abnormally higher on the dilution series compared to the 
standard test, giving 10849 data points (Figure 4B).  This left 330 data points in the prozone 
indeterminate (or unclassified) group. 
Data analysis code was written in R version 3.6.2. 
4. Results 
From a cohort of 460 post-transplant patients, 168 were positive for the Labscreen® Mixed 
assay of which 142 were positive for class I HLA-specific antibody. Five of these either did 
not have sufficient serum to undergo further iterations of testing or had failed to achieve 
adequate controls (a positive control of ≥2000 and a negative control value of ≤1500).  
Furthermore, 11 samples had insufficient bead counts, thus 126 were eligible for further 
testing with the assay modifications (Supplementary File – S. Figure 2).   
In order to minimise the confounding effect of spurious samples (mislabelling, operator 
error, unknown phenomena), a quality control (QC) correlation analysis was performed to 
identify completely un-associated samples (non-significant p-values from linear modelling 
between different test results from the same sample). The analysis used only log MFIs <9.5 
to eliminate the influence of beads affected by CMI.  Nine patients who did not show 
sufficient association were excluded from the analysis, based on the QC step.  Thus, a single 
serum sample from 117 patients were analysed with the assay modifications amounting to a 
total of individual 11349 bead reactions.  The reasons for sample exclusion are details in the 
Supplementary File (Table S1). 
4.1 Linear modelling analysis 
Linear regression analyses (outliers removed) were performed between the standard test 
and EDTA, BSC and 1 in 10 dilution modifications to determine trend lines and derive 99% 
prediction intervals (see Figure 2), which were mapped onto the whole dataset (no outlier 
12 
 
removal).  Those values beyond the prediction intervals can be thought of as outliers (i.e. 
not expected by the natural variation of the assays) and these will be analysed in greater 
detail in the following section.   
The linear models were used to suggest a nominal equivalent to the locally used standard 
assay MFI threshold of 2000 (log MFI = 7.6) adopted in this analysis for the EDTA and BSC 
modifications. The trend lines predict an average EDTA equivalent at MFI = 2097.4 (log MFI 
= 7.65) and BSC MFI = 2032.9 (log MFI = 7.62). The minor differences in MFI cut off do not 
relate to the assays’ performance, but acknowledge a slightly higher average MFI in both 
EDTA and BSC compared to the standard assay, which is adjusted for in the onward analysis.  
As expected, there is heterogeneity in the following areas:  i) the lower MFIs despite 
logarithmic transformation; ii) a cluster of data points at ~log MFI 10 on the y axis 
(representing the assay permutations) but lower values (log MFI from 5 to 8.5) on the x axis 
(representing the standard assay) - the putative prozone effect/steric hindrance cohort.  
With these exceptions noted, the data have a distinct linear relationship on each plot, and 
can be considered to reveal an association between the two assay types (assuming no 




Figure 2: Log normalised MFI values for A) Standard (x axis) and EDTA (y axis); B) Standard (x 
axis) and BSC (y axis); C) Standard (x axis) and 1:10 Dilution (y axis); D As in C but with colour 
coding to delineate prozone positive (green), prozone indeterminate (blue) and prozone 
negative (pink). The linear model (blue line) was fitted on the values within the rectangular 
boxed region to exclude outliers in A-C. The 99% prediction intervals from the model are 
displayed as blue dashed lines in A-C. Horizontal lines are displayed for MFI = log (2000), to 
indicate the typical threshold used in the laboratory for a positive test result in A-C. Inset 




4.2 Outlier Analysis 
Using the 99% prediction interval technique 1200 (10.6%) (standard versus EDTA), 1227 
(10.8%) (standard versus BSC) and 683 (6%) (EDTA versus BSC) outlier beads were identified.  
To ensure that obviously negative reactions were not included in the outlier analysis , at 
least one of the log MFIs had to be ≥7.6 (log 2000) normalised MFI.  There were 142 
(standard versus EDTA) and 121 (standard versus BSC) outlier beads identified using this 
inclusion criterion (see Figure 3). 
The patterns in Figure 3A and 3B are very similar, again demonstrating the cluster of beads 
around the log MFI 9.5-10 on the y axis which are clear examples of CMI.  A second 
prominent feature is that most of the beads have a log MFI above the 99% PI i.e. higher than 
expected for the alternative test compared to standard:  135 / 143 (95%) in the EDTA versus 
standard comparison and 96/119 (81%) in the BSC versus standard comparison.  Those 
beads were candidates to be considered as CMI reactions, recovered by EDTA or BSC assay 
variants.   
Figure 3C and zoomed panel show the EDTA and BSC comparison, with several clusters 
marked (i – v). Cluster i) has outliers (both data sets) with log MFI > 9 on both EDTA and BSC 
tests, beyond the upper 99% prediction interval from the standard test indicating prozone 
recovery on both tests. Cluster ii) contains ~15 SAB results with log MFI of around 10 for 
EDTA, but a range of values for BSC, log MFI 7 to 8, indicating a high signal from the EDTA 
test but a mid-range signal from the BSC test indicating that EDTA is more efficient in 
mitigating CMI in these instances. Cluster iii) contains SAB results mostly flagged as outliers 
on either EDTA testing only or both tests, with a range of MFI values and an apparent linear 
relationship; potentially indicating a weak prozone effect recovered by both tests or natural 
variation within the test. Cluster iv) contains 14 SAB results where the signal for BSC is 
considerably higher than EDTA. They have been classified as outliers in some cases since the 
EDTA signal was lower than expected (blue colour), BSC was higher than expected (red 
colour) or EDTA was unusually low and BSC was unusually high (“Both”, coloured red). Six of 
these results came from one sample (15.6506188 – see Supplementary File 1 for source 
data), in which EDTA, standard test and dilution assay all find all SAB results to be negative, 
but BSC testing has seven positive (>2000 MFI) results. The origin of this disparity is unclear, 
but there is no supporting evidence (e.g. from dilution assay) that these are CMI cases 
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discovered by BSC testing, but missed by EDTA testing. Cluster v) shows 15 results were 
EDTA has a higher log MFI (7.5-9) than the BSC assay log MFI (5.5-7) – classed as low outliers 
on the BSC test i.e. the EDTA values are concordant with the standard test, but BSC signal 
was outside the lower range of normal. The results overall in Figure 3 point towards EDTA 
having an improved ability to abrogate prozone.  
Figure 3:  Outlier bead natural log MFIs for a) standard (x axis) versus EDTA (y axis); b) 
standard (x axis) versus BSC (y axis); c) All results in A or B, plotted for BSC (x axis) versus 
EDTA (y axis), colours indicating from which data set they originated) Clusters i-v indicate 
outlier beads defined based on falling outside the 99% prediction interval and at least one 
value having MFI > log 2000 (or the equivalent predicted thresholds for EDTA and BSC 
testing). Zoomed region is annotated with the sample identifiers, where they do not 
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overlap. The supplementary information contains a version of the plot annotated also with 
the antigen type of the bead, and all samples annotated. 
4.3 Defining and Detecting Prozone 
To corroborate the findings of the EDTA and BSC assays, a fixed 1 in 10 dilution SAB was 
performed for each sample in the analysis.  A dilutional assay permutation can 
simultaneously provide information about prozone affected samples and the effect of steric 
hindrance.  A simple regression analysis was performed for the standard assay versus the 1 
in 10 dilution in the same way as for the EDTA and BSC assays.  A subset regression analysis 
of the log MFIs 5-9.5 was calculated and the trend line and 99% PI mapped onto the original 
dataset (see Figure 2C). 
The pattern observed for EDTA and BSC when plotted against the standard assay is seen 
again for standard versus 1 in 10 dilution with the cluster of MFIs around 9.5-10 on the y 
axis indicating significantly higher MFIs with dilution. 
The results of the linear regression between the standard assay and fixed 1 in 10 dilution 
have enabled the following analysis, which aims to establish the sensitivity and specificity of 
EDTA and BSC assay permutations in abrogating prozone effect. 
4.4 Determining Sensitivity & Specificity 
As described in the Materials and Methods section,  the sensitivity and specificity of the 
EDTA and BSC modifications, were determined using the standard versus fixed 1 in 10 
dilution assays to facilitate identification of prozone positive, prozone negative and prozone 
indeterminate candidates (Figure 2D).  One hundred and seventy prozone positive 
reactions, 330 prozone indeterminate and 10849 prozone negative reactions were 
identified. 
Figure 4A shows the box plots for the standard assay MFIs in prozone positive and prozone 
negative groups.  As expected the MFIs are appreciably higher for the prozone positive 
cohort, but with a median MFI of log 7.5, just under the positive threshold.  From Figure 4B 
we can observe two clusters. Cluster i) contains results with a range of values from the 
standard test (log MFI 5 – 9) and the three alternative tests giving similarly high values (log 
MFI > 9), with no clear linear relationships between the standard test and the alternatives.  
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Cluster ii) contains a range of values on both axes indicating linear relationships between 
the standard test and alternative tests remain largely intact. Figure 4C shows the “prozone 
negative set” in which there is a clear underlying linear relationship between all the 
alternative tests and the standard test; the dilution series as expected has significantly lower 
MFI values than other tests. BSC and EDTA have a similar range of values.  
Figure 4D shows a ROC plot (true positive rate versus false positive rate), testing the ability 
of EDTA and BSC to differentiate prozone positive versus prozone negative cases. The input 
data was ordered by the MFI value on the EDTA test or BSC respectively. For this analysis, a 
subset of data, whereby all data points (prozone positive and negative) with MFI < 1000 
(conservative negative) on the standard assay were assessed. Under ideal conditions, only 
(and all) the prozone positive samples would have MFI > threshold defined above (2097.4 




Figure 4 We have defined two sets of SAB results – as suspected “prozone positive” and “prozone negative” (see Methods). A) Boxplots for the 
two sets, showing the log MFI values from the standard test. SAB results (log MFI) from the EDTA, BSC and Dilution tests (y-axis) versus the 
standard test (x-axis) for B) suspected prozone positive cases with two clusters determined visually (further discussed in the text), and C) 
prozone negative cases. D) A ROC plot showing the ability of EDTA and BSC tests to detect prozone positive versus prozone negative, with the 
threshold MFI indicated at the point of sensitivity (MFI 2097.4 for EDTA and 2032.9 for BSC). A subset of data was used for the ROC analysis, 
whereby all data points (prozone positive and negative) had MFI < 1000 (conservative negative) on the standard assay. 
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4.5 False positive analysis 
The data demonstrate that both EDTA and BSC testing can abrogate the prozone effect. 
However, it is also important to consider whether EDTA and BSC testing can lead to false 
positive results.  This facet is particularly challenging to test, since there is no “gold 
standard” to define a true negative.  
To create a data set which we were reasonably confident was composed only of true 
negatives, more conservative thresholds were applied. Only SABs giving results from the 
standard assay MFI < 1000 and the dilution series MFI < 208 (predicted linear equivalent 
from Figure 2C) are called negative. We then plotted the results of this subset of data, and 
classified whether they were deemed positive by EDTA or BSC tests, at the equivalent 
predicted thresholds (compared to >2000 for the standard assay), as shown in Figure 5. For 
this set of confident negative reactions, there are only a few instances of EDTA or BSC 
testing giving positive results, using the suggested thresholds from linear modelling, with 
false positive rates of 0.004 and 0.002 respectively.  
 
Figure 5 Scatter plots of the log MFI values for “true negative” result set (see main text for 
definition) for A) EDTA testing (y-axis) versus dilution assay; and B) BSC assay versus dilution 
assay. The horizontal line shows the threshold for a positive result: log MFI > log (2124) for 




4.6 False Negative Detection 
A set of SAB results were defined as true positives where the standard test MFI > 4000 and 
the dilution assay was > 640.7 (the equivalent threshold to 4000 determined by the linear fit 
of dilution to standard) – giving 936 test results. The rationale for these thresholds is that 
using an MFI close to the threshold of 2000 could easily fall  below it on re-testing. A value 
of 4000 on the standard assay, and “confirmed” on the dilution assay with a comparatively 
high value is unlikely to be a true negative result. Using the previously defined positive 
thresholds for EDTA and BSC tests, results were classified as false negatives if they fell below 
these positive thresholds (2097 for EDTA and 2033 for BSC). As shown in Figure 6, only one 
false negative was detected by EDTA testing (FNR = 0.0011) and 13 false negatives were 
detected for BSC testing (FNR = 0.0139). Notably, 10 out of 13 test results were all derived 
from the same BSC sample (14.60692 – see Supplementary File 1 for raw data), described in 
section 4.2.  
 
Figure 6 Scatterplot showing log MFI values for the “true positive” set n =885 (see main text 
for definition) for A) EDTA versus standard assay and B) BSC versus standard assay.  





4.7 Population Analysis 
In our population analysis, we identified that all 170 prozone positive reactions were 
derived from sera from 23/117 (19.7%) patients tested with standard SAB and 
modifications.  Using our new tool to define prozone positivity, these values are 
considerably lower than those described by others in both population and highly sensitised 
groups[9], [13]–[15]. Of the 170 prozone positive beads, 80 (47.1%) were HLA-A specificities, 
78 (45.8%) HLA-B and 12 HLA-Cw (7.1%) representing 52% (HLA-A), 65% (HLA-B) and 26% 
(HLA-Cw) of the samples.  Examining the whole population of reactions at the standard 
assay threshold MFI of 2000 reveals 1565 positive results of which 564 (36%) were directed 
against HLA-A, 902 (55.5%) against HLA-B and 141 (8.4%) against HLA-Cw. 
 
Figure 7 Full population analysis, plotting the log MFI for the three test types as A) boxplots; 
B) density plot; using the linear model predicted thresholds for EDTA and BSC, equivalent to 
standard test MFI > 2000. 
The whole population analysis is shown in figure 7 which enabled determination of the 
relationship between MFI distributions in the standard, EDTA and BSC assays.  We have 
referred to this at multiple points during the paper and it is this large data series that has 
enabled our estimation of different threshold MFIs for EDTA (2097) and BSC (2033) for 
determining positivity based on a single point cut-off.  Using these thresholds, 1730 SABs 
gave a positive test for EDTA, 1671 for BSC and 1565 for the standard assay. While this is a 
substantial number of additional positives from EDTA testing (165 more) – as demonstrated 
22 
 
above, almost all of these were explained by the prozone effect, and we do not see 
evidence of false positive results in the EDTA set. 
 
Figure 8: A) All bead results for prozone positive samples (N=23) showing prozone positive 
beads (green), prozone negative beads (pink) and prozone indeterminate (blue).  
Finally, our prozone positive population data allows for a more detailed inspection of the 
prozone indeterminate data points  (n=330), which seems an acceptable unassigned rate of 
2.9%.  Figure 8 shows all data points for the 23 samples deemed to have at least one 
prozone positive bead.  Two hundred and thirteen of the 330 (64.5%) prozone unclassified 
data points belong to the 23 prozone positive samples (19.7% of the total samples tested).  
This group of indeterminate results may belong to the prozone positive dataset as these 






5.  Discussion 
To our knowledge, this is the first population-based post-transplant cohort study to examine 
the prozone phenomenon.    It is also the first description of a large study examining the 
ability of the BSC to ameliorate prozone when compared to a more thoroughly investigated 
alternative assay, EDTA, and a natural validation test, a 1 in 10 dilution.  Previous studies 
investigating BSC have used serum from small numbers of patients (10 for class I HLA 
specific antibody), which have been investigated because of suspicion of prozone either 
with prior EDTA testing or discrepancies with cross-matching[10], [12]. 
Modifications to the standard SAB assay have been described previously which 
abrogate/reduce the prozone effect. These include serial dilutions[14], use of the C1q 
assay[14], [19], EDTA treatment[9], [14], [20], [21] and the dual antibody rapid test (DART) 
which combines the standard SAB test with a C3d assay; the latter assay looks for C3d 
complement cleavage products[4], [9], [20], [22]–[25]. To date, there is no consensus about 
which modification offers the most effective strategy to tackle the prozone effect.   
We described the EDTA and BSC assays and how they ameliorate prozone compared to a 
fixed 1 in 10 dilution approach as a “natural” assay validation.  We observed that both EDTA 
and BSC are effective in mitigating prozone. Using ROC curve analysis, we observed that BSC 
and EDTA have very low false positive (0.002 and 0.004 respectively) and false negative 
(0.0139 and 0.006 respectively) detection rates.  The false positive reactions in Figure 5 have 
been defined on the basis that they have not been confirmed as prozone positive reactions 
by a high MFI in the dilution assay.  We do acknowledge that there are a small number of 
reactions which demonstrate such high levels of CMI that they require titres up to 1:1024 
and are therefore not revealed by a lower titre of 1:10[14].   
As described, most of the false negative reactions in the BSC analysis are derived from 1 
sample and we, thus, cannot conclude it would have a higher false negative rate than EDTA 
if more widely adopted.  The ROC plot shows EDTA has a sensitivity ~0.9 at close to zero FPR 
(and best performance achieved close to the 2097 threshold). BSC performance was still 
good, with ~0.6 sensitivity at 0 FPR. This means however that around 40% of prozone 
positive cases were not recovered by BSC testing, but only 10% by EDTA.   The EDTA assay is 
cheaper and less time consuming as it does not require a tertiary step as in the BSC assay, 
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although it does require the sera to be pre-treated and may result in a slight dilutional effect 
(EDTA occupies 5% of the treated serum volume) which may account for the wider 
prediction interval seen for EDTA compared to BSC in Figures 2A and B. 
Using prediction intervals, we described how the EDTA and BSC assays can be related to the 
standard assay in terms of MFI.  Specifically, we described suggested thresholds for these 
assays in a clinical laboratory setting (using a positive MFI threshold in the standard assay of 
2000 consistent with our local practice) in order to avoid classifying unacceptable antigens 
where true positivity does not exist.  We do, however, acknowledge that there are many 
cases of genuine antibody positivity at MFI <2000, but report our findings on the basis of 
local laboratory practice.  Of particular concern are the public epitopes such as Bw4 / Bw6 
[26] and those described by El-Awar et al. such as epitopes 422 (shared by 6 HLA-As) and 21 
(shared by  10 HLA-Bs) [27]which are expressed on many of the single antigen beads and 
whose significance can be disproportionately under-estimated by individual MFI values.  
Studies indicate that such public epitopes are frequently observed following kidney 
transplant (seen in >90% of recipients with class I HLA-specific antibody post-transplant) 
[28]. 
Concerns regarding over-estimation of EDTA MFIs resulting in assignment of additional 
positive specificities which may not be truly positive and may be a barrier to transplantation 
are not warranted for two reasons.  Firstly, using our derivation (based solely on the linearly 
associated MFI range, which excludes the prozone positive reactions), there is only a 4.9% 
gain in MFI cut-off with EDTA which is substantially less than the intrinsic variation of the 
standard assay (which can be up to 62% coefficient of variation in a non-standardised 
setting over a full range of MFIs)[14], [29].  Secondly, we have now provided a new cut-off 
which is applicable locally, providing a framework for other laboratories considering 
adopting an adjusted threshold for EDTA treatment using the same principle to ensure that 
no additional specificities are assigned positive. 
Outliers were statistically defined with PIs, affording the opportunity of their detailed 
analysis.  Outliers were classified as three different types:  a) putative prozone; b) those 
following the natural assay trend but at its very outer limits and c) potential assay failures.  
The small proportion of beads falling below the 99% PI in 3A and 3B (5% and 19% 
respectively) show a significantly higher log MFI with the standard assay in comparison to 
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either EDTA or BSC.  The majority of these values cluster close to the cut-off for the (99%) 
prediction interval, indicating that they may represent “natural” variation in the tests. In 
both Figure 3A and B, there are fewer than 10 values that have a considerably higher log 
MFI value on the standard test compared to the alternative i.e. not close to the prediction 
interval, which might be indicative of random test failures for EDTA or Biotin, or an 
undescribed scientific phenomenon which compromises the detection of CMI by EDTA or 
BSC.  
The supplementary material contains frequency tables of the number of times each 
particular bead falls into the outlier category and prozone positive subset (Supplementary 
Figures S3/4).  We did not detect any particular trend indicating certain beads were outliers 
more frequently than others.  We have not examined outliers which have negative MFIs on 
both assays of which there are 1058 in the standard / EDTA analysis and 1106 in the 
standard / BSC analysis.  It is possible that there is CMI in these reactions (most of the values 
are above the prediction intervals in Figures 2A and B), but given that they have low MFIs on 
standard and EDTA/BSC assays and the dilution assay has not identified any unexplained 
high MFI in the false negative analysis, any potential effect is unlikely to be significant.  
We classified >97% of beads as prozone positive or negative with a reasonable degree of 
certainty.  Using our definition, 1.5% (170/11349) of bead reactions demonstrate prozone; 
Tambur et al. previously described 0.5% of bead reactions demonstrating prozone in a 
selected population examining both class I and class II HLA-specific antibody[14]. In the 
prozone positive cohort, 47% of reactions were directed against HLA-A, 46% against HLA-B 
and 7% against HLA-Cw, representing 52%, 65% and 26% of the prozone positive samples 
(n=23) respectively.  The positive reactions in the total population are richer in HLA-B (56%) 
compared to HLA-A (36%).  Guidicelli et. al also describe a predominance of HLA-A 
reactivity, but in their prozone positive cohort 71% of samples had HLA-A interference.  The 
difference probably relates to different methodology used in prozone quantification [15].  
HLA-Cw appears consistently lower both in overall terms of antibody prevalence and 
susceptibility to prozone in our study and in the published literature [13], [15]. 
Although further interrogation of the prozone indeterminate cohort is outside the scope of 
the paper, the overall pattern indicates that with larger cohorts and more specific dilutional 
titrations, it may be possible to further refine prozone positive, negative and indeterminate 
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definitions. The possibility of prozone in the confidently negative samples i.e. those not 
reaching a positive result in any of our assay permutations has not been explored but has 
been described in the literature for antibodies with an exceptionally high titre (≥256) where 
EDTA fails to abrogate prozone[14].  The Flexmap 3D® instrument may offer an advantage in 
detecting high level of antibody[11].  In addition, we acknowledge that the samples which 
were excluded on the QC analysis may represent interesting biology and true antibody 
activity due to undescribed interactions between the beads and sera. Elucidating any such 
phenomena is beyond the scope of this paper to establish.  
We have not examined the low titre antibodies which give a high MFI signal on the standard 
test i.e those which are seen to dilute to negligible MFIs on a fixed 1 in 10 dilution.  The 
former subset of beads is difficult to characterise because many of the MFIs fall outside of 
the range observed to show a linear trend.  Such a high level of heterogeneity between 
assays at these lower MFIs makes simple deductions such as what qualifies as an outlier 
challenging enough without moving onto higher order scientific phenomena like prozone.  
The latter relies on precise dilutional titration and is outside the scope of this study. 
Another point for future consideration is any effect of prozone on the Labscreen® Mixed 
assay.  Prozone may affect this assay similarly (which is the benchmark assay used to 
establish candidate samples positive for HLA-specific antibody).  Small cohort studies from 
Cambridge[30] and Los Angeles (in respect of MICA antibodies)[31] suggest the prozone 
effect is not strongly observed in the screening assay.  However, a validation study is needed 
to establish the effects of prozone on the Labscreen® Mixed assay. 
5.1 Conclusion 
We recommend both EDTA and BSC as suitable assays to overcome prozone.  We believe 
that clinical laboratories should adopt a validated assay modification to abrogate prozone as 
routine in determining sensitisation for all potential renal transplant recipients, as the 
standard assay is susceptible to prozone in nearly 20% of a sensitised post-transplant 
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Supplementary Figure 1:  Linear regression for natural log transformed MFIs showing R2 values with 
outliers removed for a) standard (x axis) and EDTA (y axis); b) standard (x axis) and BSC (y axis); c) 




















Supplementary Figure 2: Running over 14 pages, the plots present the MFI intensity for the standard 
test, EDTA, Biotin and Dilution series for 137 samples tested. The 20 samples indicated did not meet 
quality control thresholds, and were excluded.  
Supplementary Table 1:  Table to show reasons for sample exclusion 
Reason for Exclusion Samples Affected 






















Supplementary Figure 3:  Frequency table to show the number of times each bead falls into the outlier category:  EDTA=blue bars; BSC=orange bars. 
  
 
Supplementary Figure 4:  Frequency table to show the number of times each bead falls into the prozone positive category
 
